2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
390
Other hematologic neoplasm
259
Dermatologic
206
Plasma cell
124
Myeloid
98
Sarcoma
77
CNS
40
Other neoplasm
31
Genitourinary
29
Classical hematology
24
Breast
23
Gynecologic
22
Thoracic
19
Gastrointestinal
19
Head & Neck
7
Endocrine
6
Other solid neoplasm
2
NET
2
Other
1
Conditions
Neuroendocrine Tumors
531
Gastro-enteropancreatic neuroendocrine tumor
58
Carcinoid Tumor
58
Neoplasms
49
Carcinoma, Neuroendocrine
44
Pancreatic Neoplasms
36
Adenoma, Islet Cell
33
Neoplasm Metastasis
28
Pheochromocytoma
25
Colorectal Neoplasms
24
Paraganglioma
23
Stomach Neoplasms
21
Breast Neoplasms
21
Prostatic Neoplasms
20
Lung Neoplasms
20
Carcinoma, Hepatocellular
20
Sarcoma
19
Carcinoma
19
Thyroid Neoplasms
18
Gastrointestinal Neoplasms
18
Neuroblastoma
15
Cholangiocarcinoma
14
Carcinoma, Renal Cell
14
Small Cell Lung Carcinoma
13
Melanoma
13
Esophageal Neoplasms
13
Serotonin Syndrome
12
Colonic Neoplasms
12
Brain Neoplasms
11
Adenocarcinoma
11
Interventions
entrectinib
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Large-Cell, Anaplastic
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts